Biotech
-
-390x220.jpg)
After 4 years, it’s a no from Sanofi as it punts MyoKardia drug program deal
[ad_1] French Big Pharma Sanofi is strolling away from a coronary heart drug illness pact with MyoKardia forward of knowledge…
Read More » -
Oxford Immunotec to Present at the 37th Annual J.P. Morgan Healthcare Conference Nasdaq:OXFD
[ad_1] OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a world,…
Read More » -
Novo bags €430M Staten buyout option to boost cardiovascular disease pipeline
[ad_1] Novo Nordisk has landed an option to buy Staten Biotechnology in a €430 million ($485 million) deal. The agreement…
Read More » -
Doug Disraeli D.D.S. Offers Tips on How to Stick to Your Daily Flossing Resolutions
[ad_1] SAN DIEGO, Dec. 28, 2018 (GLOBE NEWSWIRE) — With the vacation season amongst us, Dr. Doug Disraeli is aware…
Read More » -
Harpoon files $86M IPO to help fund its T-cell engager platform
[ad_1] Fresh off elevating $70 million by a collection C spherical simply over a month in the past, Harpoon Therapeutics…
Read More » -
Innovent buys Chinese rights to Incyte drugs for $40M upfront
[ad_1] Innovent Biologics has bagged the Chinese rights to three clinical-phase oncology and hematology drugs in growth at Incyte. The…
Read More » -
Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer
[ad_1] Australian biotech Imugene says its HER2 vaccine hit the mark in a part 1b trial, establishing a part 2…
Read More » -
Entrada emerges with $59M to fund the delivery of biologic therapies into the cell
[ad_1] Entrada Therapeutics has debuted with a $59 million sequence A and a plan to ship biologic therapies intracellularly to…
Read More » -
Idorsia’s selatogrel hits goals in phase 2 cardiovascular trials
[ad_1] Idorsia’s P2Y12 receptor antagonist selatogrel has considerably inhibited platelet aggregation in two phase 2 trials. The major endpoint successes…
Read More » -
Sophiris slides on prostate cancer data but vows to press on
[ad_1] Sophiris Bio is adamant that it’s going to advance its lead drug topsalysin into section 3 testing, after a…
Read More »
